Our mission is

to contribute to well-being of humanity by treating chronic immune diseases through peptide drugs we discover and develop.

Thank you for visiting our website.

KINE SCIENCES is a company that develops ultra-small peptide innovative medicines based on functional immunomics.

We discovered the function of a novel cytokine ERDR1 for the first time in the world and since we have been developing drug candidates of ultra-small peptide with private and public funding including the one from Korea Drug Development Fund for consecutive four years.

The diseases we aim to treat are chronic immune diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, psoriasis, cancer, Alzheimer’s disease, and many rare immune diseases.

Though we live in an era when we see more research on life sciences and more drugs on the market than any other era of human history, we humans have yet to find cures for these chronic immune diseases by seeing occurrence of resistance or relapse which make lifelong treatment of expensive medicines inevitable for patients.

These diseases put a great burden not only on patients themselves but their families and the society as a whole.

KINE SCIENCES is committed to treating chronic immune diseases, making lives of patients and their families better, and ultimately improving well-being of humanity by developing safer, more economical and more convenient medicines of ultra small peptides.

Please give us encouragement and support for our daunting journey.


  • Dae Ho Cho Ph.D

  • Ph.D, Chicago Medical School; B.S., SUNY

    Professor of Convergence Research Institute, Korea University

    Head of Nano Bio material Research Center, Korea University

    Professor of Department of Life Sciences, Sookmyung Women's University


Hee Kyung Kim MBA

M.S, Business Administration, Sogang University, Bachelor of Pharmacy, Seoul National University

Senior Vice President, Head of Clinical Science Division & Regulatory Affairs Team, Samsung Bioepis

Vice President, Strategic Business Development, Samsung Electronics

Executive Director, Head of Market Access Division & Compliance, Novartis, Pharma

Manager, Regulatory Affairs, Baxter

Seung Bo Moon CPA

B.S., Business Administration, Korea University

CFO and COO of Hanel

CFO of Meere Company

CPA of Samil PwC

Byoung Jin Seo MBA

M.S, Business Administration, Korea University

Vice President of Strategic Planning & BD, NKMAX

General Manager of M&A, Samsung Fire & Marine

Project Manager, A.T.Kearney

Consultant, Accenture

Head of
Research Team
Myun Soo Kim Ph.D

Ph.D & B.S, Korea University

Research Professor of Institute of Convergence Science, Korea University

Research Professor for BK21PLUS Project, Korea University

Senior Researcher, Sookmyung Women’s University

Head of
Strategic Planning Team
Hyun Gun Song Ph.D

Ph.D, Chungnam National University; M.S. & B.S. Kangwon National University

Assistant Professor of Anatomy Class of Medical School, Injae University

Head of Research
Planning Team
Sun Young Park Ph.D

B.S., M.S, & Ph.D, Department of Cell Biology, Sookmyung Women's University

Senior Researcher, Sookmyung Women's University

Senior Researcher, SIS Immunology Research Center, Sookmyung Women's University

Research Professor, Sookmyung Women’s University

Head of
immune-neurology Team
Chang Kyu Gu Ph.D

B.S., Hankuk University of Foreign Studies Ph.D., Hallym University

Instructor, Massachusetts General Hospital and Harvard Medical School

Senior Scientist, Walden Biosciences


  • 09
    KINE-101A Phase 1 IND approved by US FDA
    Substance patents regarding KINE-101, KINE-201 and KINE-301 registered in US


  • 07
    Project awarded by Korea Patent Strategy Development Institute


  • 03
    Change of corporate name to KINE SCIENCES Co.,Ltd.
    R&D Center of KINE SCIENCES established
    KINE-101A GLP study initiated
    Corporate R&D Center certification acquisition


  • 10
    Established joint research institute with Korea University
    Certified by Korea Government as a Venture Company


  • 12
    Patents regarding KINE-101, KINE-201 and KINE-301 filed in major foreign conturies


  • 08
    Company founded(Bio Pep Co., Ltd.)
    Selected as a new drug development project by the Ministry of New Drug Development Project
Contributing to better lives of mankind
by developing innovative therapies
Vision 2025
Growing as a unicorn company
carrying out more than five global clinical trials with new molecules

Core Value

    Pursuing the best through change and innovation
    Being flexible and adaptable to ever-changing environment
    Sticking to the principle and being honest
    Being committed to common goal and vision
    Moving forward hand in hand
Continuous InnovationRaises Hope for Humanity.